

Validation of World Health Organisation HIV/AIDS Clinical Staging in Predicting Initiation of Antiretroviral Therapy and Clinical Predictors of Low CD4 Cell Count in Uganda

Steven Baveewo^{1,6*}, Francis Ssali⁴, Charles Karamagi¹, Joan N. Kalyango^{1,2}, Judith A. Hahn⁵, Kenneth Ekoru¹, Peter Mugenyi⁴, Elly Katabira³

1 Clinical epidemiology unit, College of Health Sciences, Makerere University Kampala, Kampala, Uganda, **2** Department of Pharmacy, College of Health Sciences, Makerere University Kampala, Kampala, Uganda, **3** Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda, **4** Joint Clinical Research Centre Kampala, Kampala, Uganda, **5** University of California San Francisco, San Francisco General Hospital, San Francisco, California, United States of America, **6** Makerere University - University of California Los Angeles - University of California San Francisco VCT research collaboration, Kampala, Uganda

Abstract

Introduction: The WHO clinical guidelines for HIV/AIDS are widely used in resource limited settings to represent the gold standard of CD4 counts for antiviral therapy initiation. The utility of the WHO-defined stage 1 and 2 clinical factors used in WHO HIV/AIDS clinical staging in predicting low CD4 cell count has not been established in Uganda. Although the WHO staging has shown low sensitivity for predicting CD4 < 200 cells/mm³, it has not been evaluated at for CD4 cut-offs of < 250 cells/mm³ or < 350 cells/mm³.

Objective: To validate the World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy in a low-resource setting and to determine the clinical predictors of low CD4 cell count in Uganda.

Results: Data was collected on 395 participants from the Joint Clinical Research Centre, of whom 242 (61.3%) were classified as in stages 1 and 2 and 262 (68%) were females. Participants had a mean age of 36.8 years (SD 8.5). We found a significant inverse correlation between the CD4 lymphocyte count and WHO clinical stages. The sensitivity the WHO clinical staging at CD4 cell count of 250 cells/mm³ and 350 cells/mm³ was 53.5% and 49.1% respectively. Angular cheilitis, papular pruritic eruptions and recurrent upper respiratory tract infections were found to be significant predictors of low CD4 cell count among participants in WHO stage 1 and 2.

Conclusion: The WHO HIV/AIDS clinical staging guidelines have a low sensitivity and about half of the participants in stages 1 and 2 would be eligible for ART initiation if they had been tested for CD4 count. Angular cheilitis and papular pruritic eruptions and recurrent upper respiratory tract infections may be used, in addition to the WHO staging, to improve sensitivity in the interim, as access to CD4 machines increases in Uganda.

Citation: Baveewo S, Ssali F, Karamagi C, Kalyango JN, Hahn JA, et al. (2011) Validation of World Health Organisation HIV/AIDS Clinical Staging in Predicting Initiation of Antiretroviral Therapy and Clinical Predictors of Low CD4 Cell Count in Uganda. PLoS ONE 6(5): e19089. doi:10.1371/journal.pone.0019089

Editor: Malcolm Gracie Semple, University of Liverpool, United Kingdom

Received: October 6, 2010; **Accepted:** March 28, 2011; **Published:** May 12, 2011

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: The research was funded by the first author for a Masters thesis. He was allowed free access to the Joint Clinical Research centre patients and laboratory facilities. Since it was a Masters thesis, as the first author SB was involved in study design, data collection and analysis, decision to publish, or preparation of the manuscript. SB was assisted by the all the co-authors at all the various stages of conducting research and developing this manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: baveewosteven@yahoo.co.uk

Introduction

There have been significant declines in HIV-related morbidity and mortality since the advent of anti-retroviral therapy (ART) [1,2]. Initiation of ART is based on CD4 cell count or being classified as being in World Health Organisation (WHO) HIV/AIDS clinical stage III or IV [2]. However, although the CD4 cell counts testing is critical in the determination of eligibility for ART, many HIV treatment centres in resource limited settings lack CD4 testing facilities. In the absence of CD4 testing in rural primary health care facilities, WHO HIV/AIDS clinical staging is used to recommend when to initiate ART [2,3].

Some previous studies have explored the utility of using other predictors of low CD4 cell count to guide initiation of antiretroviral therapy. Other clinical factors, such as anaemia and body mass index have low sensitivities in detecting eligibility for HAART initiation [4] while other studies have shown that clinical factors such as anaemia could double sensitivity if used together with the WHO clinical staging guidelines [5]. Total lymphocyte counts < 1200 cells/microl used with WHO staging showed good specificity (>99%) [5], and a good correlation between total lymphocyte count and CD4 cell count in a Ugandan study [6].

In Uganda, although the availability of CD4 testing is increasing, its access is limited due to cost and a lack of laboratory

infrastructure, particularly in rural health facilities. Specifically, CD4 testing is not available in decentralized health units that include district hospitals and health centre IV facilities that serve the largest population of HIV-infected Ugandans.

The WHO clinical staging system for HIV/AIDS was developed in 1990 and revised in 2007. It uses clinical parameters to classify subjects into any one of four categories i.e. stage I to IV, progressing from primary HIV infection to advanced HIV/AIDS. It is these categories that are used to guide decision making for the management of HIV/AIDS patients where there is limited access to laboratory services [7]. These clinical guidelines are readily available, convenient to the patient, cheap and can be applied by trained clinicians even in the most remote health facilities.

Initially the WHO clinical staging for HIV/AIDS was used in line with CD4 cut-offs of 200 cells/mm³ to make decisions on ART initiation. However, in Uganda the CD4 cut-off for ART initiation changed from 200 cells/mm³ to 250 cells/mm³ or 350 cells/mm³ for the World health organisation. Previous studies of the utility of the WHO HIV/AIDS clinical guidelines for determining ART eligibility, using the cut-off of <200 cells/mm³ have found the sensitivity to be in the range of 51–52% and the specificity to be in the range 68–88% [5,8,9]. In a Ugandan study, the sensitivity was 51% and the specificity was 88% [8].

Despite the wide use of the WHO HIV/AIDS clinical guidelines in Ugandan primary health care facilities, they have not yet been evaluated in Uganda against the new CD4 cut-offs for ART eligibility of <250cells/mm³ and <350 cells/mm³. Evaluation of the WHO HIV/AIDS staging guidelines in comparison to the newer CD4 cell count cut-offs for ART eligibility is needed to determine the potential level of misclassification. In addition, examination of the individual clinical components of the WHO HIV disease staging is needed because some clinical factors associated with stage I or II illness may be predictive of more advanced immune suppression in Uganda. We postulate that if there are significant clinical factors in stages I and II that are predictive of low CD4 counts, they could improve identification of ART-eligible subjects, thereby reducing the missed opportunities for timely ART initiation. The goal of this study was therefore to determine the diagnostic properties (sensitivity, specificity, positive predictive values and negative predictive values) of the WHO HIV/AIDS clinical staging guidelines at CD4<250cells/mm³ and <350cells/mm³ and to determine the WHO HIV/AIDS Stage I and II clinical factors (symptoms and signs) that are predictive of CD4<250cells/mm³ and CD4<350 cells/mm³.

Methods

Study area and subjects selection

To address the study objectives, we conducted a multi-centre, cross-sectional study from January to April 2007 at three JCRC sites located at Mengo (in Kampala, the capital city of Uganda), Jinja (85 kilometres from Kampala) and Kasana (45 kilometres from Kampala). All the three sites offered free HIV/AIDS treatment and care at the time of study recruitment. The study sites were selected for convenience. The number of subjects enrolled from each site was proportional to the number of ARV treatment naïve HIV patients seen at each study site in the previous 3 months. Subjects aged ≥18, known HIV positive, ART treatment naïve, and consented to participate in the study were consecutively enrolled to participate in the study.

Data Collection Procedures

Clinicians with training in HIV/AIDS clinical staging administered structured questionnaires to study participants. They

recorded the socio-demographic data (age, sex, marital status and occupation), and clinical factors used for the WHO HIV/AIDS staging guidelines. The latter were used to determine the patients' clinical stage [2]. Blood samples for laboratory analysis at the Joint Clinical Research Centre (JCRC) were collected after clinical staging. Complete blood count (CBC), total lymphocyte count and sputum results were used to guide the diagnosis of neutropenia, leucopenia, anaemia and presence of pulmonary tuberculosis. The need for a CBC and/or total lymphocyte count was determined by the attending physician. The laboratory staff that handled the specimens was blinded to both the patients' identities and their HIV/AIDS clinical stage. The CBC was determined by Coulter AC[®]T 5 Diff CP, while the CD4 cell count was assessed using TriTEST CD4 FITC/CD8PE/CD3 PerCP (TRUCOUNT) reagent method. Quality assurance procedures are routinely conducted to compare the results to that of external laboratories (the National Health Laboratory Services in South Africa and to the UK Neqas in the United Kingdom).

Sample size and Statistical Analysis

The minimum sample size of 385 subjects for the study was determined using the cross sectional studies with $4Z_{\alpha}^2P(1-P)/W^2$ where W is the width of confidence intervals was 1%, Z_{α} at 95% confidence interval = 1.96, with an estimate of 50% of subjects that were expected to be eligible for ART [10].

We determined the diagnostic properties of the WHO clinical staging compared to CD4<250cells/mm³ and <350 cells/mm³ and calculated 95% confidence intervals for proportions, using STATA version 10.0 (STATA Corp, College Station, TX, USA). We estimated the association between CD4<250cells/mm³ and <350 cells/mm³ and stages I and II clinical features using odds ratios at 95% confidence intervals. Variables with odds ratios and $p \leq 0.2$ at bi-variate analysis were included in a multivariate logistic regression model to determine the adjusted odds ratios for the association between clinical stages I & II clinical factors and low CD4 counts.

Ethical considerations

Ethical approval was obtained from the Faculty of Medicine Research and Ethics Committee of Makerere University, the Joint Clinical Research Centre, and the Uganda National Council of

Table 1. Distribution of 395 participants at the CD4 cut-offs of 250cells/mm³ and 350cells/mm³ by WHO HIV/AIDS clinical stages, and sex.

WHO clinical stage	CD4 cell count cut-offs				Total N (%)
	CD4≤250 n (%)	CD4>250 n (%)	CD4≤350 n (%)	CD4>350 n (%)	
I	17 (7.5)	49 (29.0)	32 (11.4)	34 (29.8)	66(16.7)
II	88 (38.9)	88(52.1)	111(39.5)	65 (57.0)	176(44.6)
III	73(32.3)	23(13.6)	83 (29.5)	13 (11.4)	96(24.3)
IV	48(21.2)	9 (5.3)	55(19.6)	2(1.8)	57(14.4)
Total	226 (100)	169 (100)	281(100)	114(100)	395(100)
Sex					
Male	87(38.5)	40(23.7)	104(37.0)	23(20.2)	127(32.2)
Female	139(61.5)	129(76.3)	177 (63.0)	91(79.8)	268(67.8)
Total (%)	226 (100)	169 (100)	281(100)	114(100)	395(100)

doi:10.1371/journal.pone.0019089.t001




Figure 1. The Box plots showing the median and Inter quartile ranges CD4 cell counts of 395 participants by the WHO HIV/AIDS clinical stages I-IV.

doi:10.1371/journal.pone.0019089.g001

Science and Technology. Written informed consent was obtained from each subject before enrolment into the study.

Results

Characteristics of the study population

Between January and April 2007 a total of 417 known HIV patients were screened. Twenty two (5.3%) participants were excluded from the study due to; age <18 years ($n = 1$), prior ART experience ($n = 2$) and inaccessible CD4 results ($n = 19$). A total of 395 participants were enrolled into the study. The subjects were enrolled from JCRC Mengo (75%), Jinja (14%) and Kasana (11%). The majority (61%) of the 395 subjects were classified as in clinical stages 1 and 2. Over two thirds, (68%) of all enrolled subjects were females. (Table 1). Three hundred and sixty five (92%) had attained primary level education and 117 (29.6%) were in the reproductive age group (18–49 years).

The median CD4 cell count of those in WHO HIV/AIDS clinical stages 1 and 2 was significantly higher than that of participants in clinical stages 3 and 4. (Figure 1) We found a highly significant but moderately strong correlation between the CD4 lymphocyte count and WHO clinical stage (spearman correlation = -0.498 , $p < 0.01$). Female participants had a significantly higher mean CD4 cell count 307.23 cells/ mm^3 (SD = 270.93) as compared to male participants with 216.77 cells/ mm^3 (SD = 226.08), ($p < 0.0012$), while the mean CD4 counts among the urban-based population was higher at 301.62 cells/ mm^3 (SD = 260.57) compared to the rural-based population with CD4 cell count of 206.03 cells/ mm^3 (248.12), $p < 0.0016$.

Diagnostic properties of the WHO HIV/AIDS clinical staging guidelines

The sensitivities of the WHO clinical staging at CD4 cell count cut-offs of 250 cells/ mm^3 and 350 cells/ mm^3 were 53.5% and 49.1%, while the specificities were 81.1% and 86.8% at CD4 counts of 250 cells/ mm^3 and 350 cells/ mm^3 . The positive

predictive values at CD4 cell count of 250 cells/ mm^3 and 350 cells/ mm^3 was 79.1% and 90.2%, and the negative predictive values were 56.6% and 40.9%, respectively. (Table 2) There were no significant differences in the sensitivities and specificities of the WHO HIV/AIDS clinical staging guidelines at the different cut offs (CD4 < 250 cells/ mm^3 and CD4 < 350 cells/ mm^3).

Stage II WHO HIV/AIDS Clinical predictors of low CD4 count

Angular cheilitis and papular pruritic eruptions (Table 3) were found to be significant predictors of CD4 cell count < 250 cells/ mm^3 while angular cheilitis and recurrent upper respiratory tract infections (Table 4) were found to be significant predictors of CD4 < 350 cells/ mm^3 in multivariate analysis. Angular cheilitis was defined as having splits or cracks on lips at the corner of the mouth with possible de-pigmentation, or having been successfully treated with an antifungal for angular cheilitis. Papular pruritic eruptions

Table 2. Diagnostic characteristics of the WHO HIV/AIDS clinical staging guidelines at the CD4 cell count of less than 250 cells/ mm^3 and 350 cells/ mm^3 among 395 participants in JCRC Mengo, Kakira and Kasana health centres, Uganda.

Diagnostic characteristics	Values at CD4 < 250 cells/ mm^3 (95% CI)	Values at CD4 < 350 cells/ mm^3 (95% CI)
Sensitivity	53.5% (47–60)	49.1% (43–55)
Specificity	81.1% (75–87)	86.8% (81–93)
Positive Predictive Value	79.1% (73–86)	90.2% (85–95)
Negative Predictive Value	56.6% (50–63)	40.9% (35–47)
False Positive	18.9% (13–25)	13.2% (07–19)
False Negative	46.5% (40–53)	50.9% (45–57)

doi:10.1371/journal.pone.0019089.t002

Table 3. Association between CD4 cell count $<250\text{cells}/\text{mm}^3$ and the clinical features of the WHO HIV/AIDS clinical Stages I and II for the 242 participants in stages 1 and 2.

Clinical features	CD4 <250 cells/ mm^3 N (%)	CD4 ≥ 250 cells/ mm^3 N (%)	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
WHO Stage I						
Asymptomatic						
Yes	17 (25.4)	50 (74.6)	0.34 (0.17-0.64)	< 0.001	0.66(0.32-1.37)	0.27
No	88 (50.3)	87 (49.7)	1		1	
PGL						
Yes	2	6	0.42(0.08-2.16)	0.29		
No	103	131	1			
WHO Stage II						
Recurrent URTI						
Yes	41(58.6)	29 (41.4)	2.38(1.34-4.26)	0.0024	1.6(0.84-3.08)	0.15
No	64(37.2)	108 (62.8)	1		1	
Moderate weight loss						
Yes	49(47.6)	54 (52.4)	1.34 (0.80-2.25)	0.259		
No	56 (40.3)	83(59.7)	1			
Herpes zoster						
Yes	22(43.1)	29 (56.9)	0.98(0.52-1.84)	0.97		
No	83 (43.5)	108 (56.5)	1			
Angular cheilitis						
Yes	20(83.3)	4(16.7)	7.8(2.47-24.75)	<0.000	4.4(1.37-14.1)	0.01
No	85(39.0)	133(61.0)	1		1	
Recurrent oral ulcerations						
Yes	21(75.0)	7(25.0)	4.64(1.84-11.71)	<0.000	2.4 (0.88-6.28)	0.09
No	84(39.3)	130(60.7)	1			
Pruritic eruption						
Yes	31(64.6)	17(35.4)	2.95(1.50-5.81)	0.001	2.1(1.02-4.34)	0.04
No	74 (38.1)	120(61.9)	1		1	
Seborrheic dermatitis						
Yes	6(60.0)	4(40.0)	2.02 (0.55-7.38)	0.280		
No	99 (42.7)	133(57.3)	1			
Fungal nail infections						
Yes	0(0)	1(100.0)	0.00	0.3813		
No	105 (43.6)	136 (56.4)	1			

doi:10.1371/journal.pone.0019089.t003

were defined as papular pruritic lesions, often with marked post inflammatory skin pigmentation; Recurrent upper respiratory tract infections were defined as current episode of upper respiratory tract infection with at least one episode in the past 6 months [11].

The effect of the clinical predictors of low CD4 cell count on sensitivity of the WHO HIV/AIDS clinical staging guidelines

To assess the effect of the use of angular cheilitis and papular pruritic eruption on the sensitivity, specificity and false negative rate to predict CD4 $<250\text{cells}/\text{mm}^3$ among patients in Stage I and II, a variable “clinical factor present” was generated if any of the patients in Stage II disease had one or both clinical factors of angular cheilitis and pruritic eruption present. Forty-four subjects out of the 63 subjects (70%) that had either angular cheilitis or pruritic eruption

had a CD4 cell count of $<250\text{cells}/\text{mm}^3$. Thus 44 subjects would have been correctly considered eligible for ART if any of the two clinical features had been used, while only 19 of the 63 subjects would have been started on ART earlier than the required time if they were considered. The identification of 44 eligible patients using the supplemental clinical symptoms of angular cheilitis and papular pruritic eruption would have improved the sensitivity of the clinical staging from 53.5% to 73.0% and subsequently reduced the false negative rate from 46.5% to 27%.

To assess the effect of the use of angular cheilitis and recurrent upper respiratory tract infections on the sensitivity, specificity and false negative rate to predict CD4 $<350\text{cells}/\text{mm}^3$ among patients in Stage I and II, a variable “clinical factor present” was generated if any of the patients in Stage II disease had one or both clinical factors of angular cheilitis and recurrent upper respiratory tract infection present.

Table 4. Association between CD4 <350cells/mm³ and the Clinical Features of the WHO HIV/AIDS clinical stages I & II among the 242 participants in Stages 1 and 2.

Clinical features	CD4<350 cells/mm ³ N (%)	CD4≥350 cells/mm ³ N (%)	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
WHO Stage I						
Asymptomatic						
Yes	31(46.3)	36(57.3)	0.48(0.27-0.86)	0.012	1.05(0.53-2.06)	0.89
No	112 (64.0)	63(36.0)	1		1	
PGL						
Yes	4	4	0.68(0.17-2.81)	0.60		
No	139	95	1			
WHO Stage II						
Recurrent bacterial URTI						
Yes	53(75.7)	17(24.3)	2.84(1.49-5.38)	<0.000	2.48(1.23-5.0)	0.01
No	90(52.3)	82(47.7)	1		1	
Moderate weight loss						
Yes	65(63.1)	38(36.9)	1.33(0.79-2.26)	0.28		
No	78(56.1)	61(43.9)	1			
Herpes zoster						
Yes	29 (56.9)	22 (43.1)	0.89 (0.48-1.67)	0.72		
No	114(59.7)	77 (40.3)	1			
Angular cheilitis						
Yes	22 (91.7)	2 (8.3)	8.82(1.94-39.99)	0.0006	5.82(1.27-26.8)	0.02
No	121(55.5)	97(44.5)	1		1	
Recurrent oral ulcerations						
Yes	23 (82.1)	5(17.9)	3.60(1.29-10.0)	0.0085	2.08(0.69-6.22)	0.19
No	120 (56.1)	94(42.9)	1		1	
Pruritic eruption						
Yes	35(72.9)	13 (27.1)	2.14(1.06-4.33)	0.03	1.56(0.72-3.39)	0.26
No	108 (55.7)	86 (44.3)	1		1	
Seborrheic dermatitis						
Yes	8 (80.0)	2(20.0)	2.87 (0.59- 13.9)	0.17	3.83(076-19.3)	0.10
No	135(58.2)	97 (41.8)	1		1	
Fungal nail infections						
Yes	1 (83.3)	0 (16.7)	infinite	0.41		
No	142 (70.9)	99 (29.1)				

doi:10.1371/journal.pone.0019089.t004

Sixty three (77.8%) of the 81 subjects that had either angular cheilitis or upper respiratory tract infections on both were found to have CD4 counts <350cells/mm³ and therefore would have been eligible for ART initiation, while only 18 of the 81 subjects would have been treated earlier than the required time if it they were considered. The identification of 63 eligible subjects using only angular cheilitis and recurrent upper respiratory tract infections would have improved the sensitivity of the clinical staging from 49.1% to 71.5% and subsequently reduced the false negative rate from 50.9% to 28.5%.

Discussion

Although the WHO HIV/AIDS clinical staging plays a critical role in guiding primary health workers in initiating antiretroviral therapy [3,12,13], some studies have reported diagnostic limita-

tions of its use [8,14,15]. Our study findings show a sensitivity of 53.5% and 49.1% for identifying CD4 counts of less than 250cells/mm³ and 350cells/mm³, respectively. Our findings replicate the low sensitivities that have been previously found in studies of the WHO staging guidelines conducted in Africa [8,14,15]. The use of cotrimoxazole prophylaxis to prevent some opportunistic infections may have contributed to the high false negative rate, despite the low CD4 counts. The low sensitivities that were found show that about half of the participants would have missed ART initiation if the WHO clinical staging guidelines alone were used, which suggests significant diagnostic challenges to the WHO/HIV AIDS clinical staging guidelines which if used alone may impact morbidity and mortality [16,17].

We found that the specificity of the WHO HIV/AIDS clinical staging guidelines were at 81.1% and 86.8% at CD4 counts of 250cells/mm³ and 350cells/mm³ respectively, which was also

similar to previous studies using various CD4 cell count cut-offs [8,9,14]. Our results showed positive predictive values at $CD4 < 250 \text{ cells/mm}^3$ and at $CD4 < 350 \text{ cells/mm}^3$ of 79.1% and at 90.2%, respectively; and negative predictive values of 56.6% and 40.9% respectively.

The finding that females had a higher mean CD4 cell count than the males is similar to previous findings that demonstrated that women in stage 1 were less likely to have a lower CD4 cell count compared to the men [18]. This may be due to the better health seeking behaviour among women.

The urban based population in this study may have had a higher mean CD4 cell count compared to the rural population because of better access to the HIV counselling and testing services leading to earlier HIV diagnosis.

In our study, we found that angular cheilitis and papular pruritic eruptions were significant predictors of CD4 cell count $< 250 \text{ cells/mm}^3$ while angular cheilitis and recurrent upper respiratory tract infections predicted a CD4 cell count $< 350 \text{ cells/mm}^3$. These results are in agreement with a Tanzanian study that found that HIV associated mucocutaneous manifestations may improve the sensitivity of the WHO staging guidelines [19]. The use of three clinical features, of angular cheilitis, papular pruritic eruption and upper respiratory tract infections might greatly improve the sensitivity of the WHO HIV/AIDS guidelines in identifying patients with WHO clinical stages 1 and 2 that are eligible to start treatment. This is the first study to demonstrate the utility of the angular cheilitis, papular pruritic eruptions and upper respiratory tract infections in identifying HIV patients with low CD4 cell count which would improve on the sensitivity of the clinical staging guidelines.

While the WHO HIV/AIDS clinical guidelines are an affordable method to determine ART eligibility, routine or low cost CD4 T-cell count, as compared with WHO HIV/AIDS clinical staging in a resource limited setting is very cost-effective for sub-Saharan Africa [20].

However, the availability of the tests and the laboratory personnel is still limited in Uganda. Therefore, determining other clinical factors that are predictive of low CD4 cell count in clinical stages I and II, will be very useful in improving the identification of subjects eligible for ART initiation until low cost CD4 cell count

testing is widely available in Uganda. We recommend that similar studies with larger sample sizes be conducted in other developing countries to assess the role of clinical predictors, in addition to WHO staging guidelines in determining equivalents to CD4 counts.

Our study had much strength; there was minimal referral bias since this was a multi centre study. Random error was minimised by having an adequate sample size for the common clinical predictors. The study was limited by a lack of sufficient sample size to detect the association between rare clinical conditions and CD4 counts below 250 cells/mm^3 and 350 cells/mm^3 . Further studies are recommended to assess the association between rare clinical features and CD4 cell counts.

WHO HIV/AIDS clinical stage misclassification was minimised by use of experienced clinicians trained in the study protocols and blinding of the clinicians to the CD4 results.

Based on the findings of this study, we recommend increased access to CD4 cell count testing machines in resource limited settings. In the interim, more study is needed to confirm the clinical features that we found to be predictive of low CD4 counts. If these results are confirmed, then ART initiation among persons with these clinical features should be started regardless of WHO HIV/AIDS clinical stage. This will go a long way in identifying more patients eligible for ART.

Acknowledgments

We are grateful for the support from the management of Joint Clinical Research Centre Mengo for permitting us to access the study participants and for the laboratory investigations and Drs. Josephine Nantiba and Dr. William Tamale who conducted the clinical staging of patients at JCRC Mengo and Kakira sites. We are very grateful to the patients who freely consented to participate in the study.

Author Contributions

Conceived and designed the experiments: SB FS CK JNK EK KE JH PM. Analyzed the data: SB. Contributed reagents/materials/analysis tools: FS PM. Wrote the paper: SB FS CK JNK EK KE JH PM. Designed and analyzed software: SB. Supervised the analysis: JH.

References

- UNAIDS (2008) Report on the global AIDS epidemic.
- WHO (2006) Guidelines for antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings towards universal access.
- Uganda MoH (2003) National Antiretroviral treatment care guidelines for Adults and Children.
- Miir G, Nakubulwa S, Watara C, Munderi P, Floyd S, et al. (2010) Evaluation of affordable screening markers to detect CD4+ T-cell counts below 200 cells/mul among HIV-1-infected Ugandan adults. *Trop Med Int Health* 15(4): 396–404.
- Costello C, Nelson KE, Jamieson DJ, Spacek L, Sennun S, et al. (2005) Predictors of low CD4 count in resource-limited settings: based on an antiretroviral-naïve heterosexual thai population. *J Acquir Immune Defic Syndr* 39(2): 242–248.
- Kanya MR, Semitala FC, Quinn TC, Ronald A, Njama-Meya D, et al. (2004) Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. *Afr Health Sci* 4(2): 94–101.
- WHO, Interim WHO (2005) Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for surveillance in Africa Region, in WHO/HIV/2005.02. World Health Organisation: Geneva, Switzerland.
- Kagaayi J, Makumbi F, Nakigozi G, Wawer MJ, Gray RH, et al. (2007) WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. *AIDS (London, England)* 21(9): 1208–1210.
- Jaffar S, Birungi J, Grosskurth H, Amuron B, Namara G, et al. (2008) Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda. *AIDS research and therapy* 5: p. 4.
- Hulley SB, Browner WS, Grady DG, Newman TB (2007) *Designing Clinical Research*, Third Edition ed. 2007: Lippincott Williams & Wilkins. 91 p.
- WHO (2007) World Health Organisation case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 19–28.
- Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, et al. (2004) Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. *AIDS (London, England)* 18(8): 1159–1168.
- Spacek LA, Griswold M, Quinn TC, Moore RD (2003) Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. *AIDS (London, England)* 17(9): 1311–1317.
- Martinson N, Steyn J, Struthers H, McIntyre J, Gray G, et al. (2005) Does WHO clinical stage reliably predict who to receive ARV treatment? in Third International AIDS Society Conference on HIV Treatment and Pathogenesis Rio de Janeiro, Brazil.
- McGrath N, Kranzer K, Saul J, Crampin AC, Malema S, et al. (2007) Estimating the need for antiretroviral treatment and an assessment of a simplified HIV/AIDS case definition in rural Malawi. *AIDS (London, England)* 21 Suppl 6: S105–113.
- Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 360(9327): 119–129.
- Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, et al. (2003) When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts $< 350 \text{ cells/microL}$. *Clin Infect Dis* 37(7): 951–958.

18. Torpey K, Lartey M, Amenyah R, Addo NA, Obeng-Baah J, et al. (2009) Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need? *International journal of STD & AIDS* 20(6): 395–398.
19. Morpeth SC, Crump JA, Shao HJ, Ramadhani HO, Kisenge PR, et al. (2007) Predicting CD4 lymphocyte count <200 cells/mm³ in an HIV type 1-infected African population. *AIDS Res Hum Retroviruses* 23(10): 1230–1236.
20. Athan E, O'Brien DP, Legood R (2010) Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings. *AIDS (London, England)* 24(12): 1887–1895.